Generation of chimeric HBc proteins with epitopes in E.coli: Formation of virus-like particles and a potent inducer of antigen-specific cytotoxic immune response and anti-tumor effect in vivo

Cellular Immunology

Volumn 247, Issue 1, 2007, Pages 18-27

  Zhang, Yan ^a   Song, Shuxia ^a   Liu, Chunyan ^a   Wang, Yue ^b   Xian, Xian ^a   He, Ying ^b   Wang, Junxia ^a   Liu, Fuying ^a   Sun, Shuhan ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor; BMDCs; CTL activity; Expression purification; HBc VLP; IFN ; Inclusion body

Indexed keywords

ALPHA FETOPROTEIN; ALPHA FETOPROTEIN 1; ALPHA FETOPROTEIN 2; EPITOPE; GAMMA INTERFERON; HEPATITIS B CORE ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; TUMOR ANTIGEN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ESCHERICHIA COLI; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN PURIFICATION; RECOMBINANT PLASMID; SURVIVAL RATE; VIRUS GENE; VIRUS LIKE AGENT; WILD TYPE;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; EPITOPES; ESCHERICHIA COLI; HEPATITIS B ANTIBODIES; HEPATITIS B CORE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASM PROTEINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; VACCINES, SYNTHETIC;

ANIMALIA; ESCHERICHIA COLI; HEPATITIS B VIRUS;

EID: 34648828469     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2007.07.003     Document Type: Article

References (33)

1. Wagner R., Deml L., Schirmbeck R., Niedrig M., Reimann J., and Wolf H. Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220 (1996) 128-140
2. Accola M.A., Strack B., and Gottlinger H.G. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J. Virol. 74 (2000) 395-402
3. McGettigan J.P., Sarma S., Orenstein J.M., Pomerantz R.J., and Schnell M.J. Expression and immunogenicity of human immunodeficiency virus type 1 Gag expressed by a replication-competent rhabdovirus-based vaccine vector. J. Virol. 75 (2001) 8724-8732
4. Qiu Z., Ou D., Hobman T.C., and Gillam S. Expression and characterization of virus-like particles containing rubella virus structural proteins. J. Virol. 68 (1994) 4086-4091
5. Lenz P., Day P.M., Pang Y.Y., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166 (2001) 5346-5355
6. Gerber S., Lane C., Brown D.M., et al. Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J. Virol. 75 (2001) 4752-4760
7. Zhou X., Berglund P., Zhao H., Liljestrom P., and Jondal M. Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus. Proc. Natl. Acad. Sci. USA 92 (1995) 3009-3013
8. Fehr T., Skrastina D., Pumpens P., and Zinkernagel R.M. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Proc. Natl. Acad. Sci. USA 95 (1998) 9477-9481
9. + cytotoxic T lymphocyte responses in vivo. J. Immunol. 152 (1994) 1110-1119
10. Clarke B.E., Newton S.E., Carroll A.R., et al. Improved immunogenicity of a peptid epitope after fusion to hepatitis B core protein. Nature 330 (1987) 381-384
11. Pumpens P., and Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44 (2001) 98-114
12. De Filette M., Min Jou W., Birkett A., et al. Universal influenza A vaccine: optimization of M2-based constructs. Virology 337 (2005) 149-161
13. De Filette M., Ramne A., Birkett A., et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24 (2006) 544-551
14. Fiers W., Neirynck S., Deroo T., Saelens X., and Jou W.M. Soluble recombinant influenza vaccines. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356 (2001) 1961-1963
15. Fiers W., De Filette M., Birkett A., Neirynck S., and Min Jou W. "Universal" human influenza A vaccine. Virus Res. 103 (2004) 173-176
16. Schwarz K., Meijerink E., Speiser D.E., Tissot A.C., Cielens I., Renhof R., Dishlers A., Pumpens P., and Bachmann M.F. Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur. J. Immunol. 35 (2005) 816-821
17. Grgacic E.V., and Anderson D.A. Virus-like particles: passport to immune recognition. Methods 40 (2006) 60-65
18. Bachmann M.F., Rohrer U.H., Kundig T.M., Burki K., Hengartner H., and Zinkernagel R.M. The influence of antigen organization on B cell responsiveness. Science 262 (1993) 1448-1451
19. Pumpens P., Borisova G.P., Crowther R.A., and Grens E. Hepatitis B virus core particles as epitope carriers. Intervirology 38 (1995) 63-74
20. Miyanohara A., Imamura T., Araki M., Sugawara K., Ohtomo N., and Matsubara K. Expression of hepatitis B virus core antigen gene in Saccharomyces cerevisiae: synthesis of two polypeptids translated from different initiation codons. J. Virol. 59 (1986) 176-180
21. Hirschman S.Z., Price P., Garfinkel E., Christman J., and Acs G. Expression of cloned hepatitis B virus DNA in human cell cultures. Proc. Natl. Acad. Sci. USA 77 (1980) 5011-5507
22. Hirschman S.Z., Garfinkel E., and Sugrue S. Expression of hepatitis B viral antigens in animal cells transfected with viral DNA. Trans. Assoc. Am. Physicians 95 (1982) 53-62
23. Schlicht H.J., and Schaller H. The secretory core protein of human hepatitis B virus is expressed on the cell surface. J. Virol. 63 (1989) 5399-5404
24. Han S.W., Zhu Q.Y., Zhao L.Q., and Fang J.M. Expression of hepatitis B core antigen gene in recombinant vaccinia virus. Chin. J. Biotechnol. 5 (1989) 141-148
25. Tsuda S., Yoshioka K., Tanaka T., et al. Application of the human hepatitis B virus core antigen from transgenic tobacco plants for serological diagnosis. Vox Sang. 74 (1998) 148-155
26. Huang Z., Santi L., LePore K., Kilbourne J., Arntzen C.J., and Mason H.S. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 24 (2006) 2506-2513
27. Wingfield P.T., Stahl S.J., Williams R.W., and Steven A.C. Hepatitis core antigen produced in Escherichia coli: subunit composition, conformational analysis, and in vitro capsid assembly. Biochemistry 34 (1995) 4919-4932
28. Song S., Wang F., He X., He Y., Li D., and Sun S. Evaluation of antitumor immunity efficacy of epitope-based vaccine with B16 cell line co-expressing HLA-A2/H-2kb and HCC-derived CTL multiepitope in HLA transgenic mice. Vaccine 25 (2007) 4853-4860
29. Inaba K., Inaba M., Romani N., Aya H., Deguchi M., Ikehara S., Muramatsu S., and Steinman R.M. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176 (1992) 1693-1702
30. He X., Jiang L., Wang F., Xiao Z., Li J., Liu L.S., et al. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting. Vaccine 23 (2005) 1649-1656
31. Petra L., Patricia M.D., Yuk-Ying S.P., et al. Papillomavirus-like particles induce acute activation of dendritic cells. J. Immunol. 166 (2001) 5346-5355
32. Cooper A., Tal G., Lider O., and Shaul Y. Cytokine induction by the hepatitis B virus capsid in macrophages is facilitated by membrane heparan sulfate and involves TLR2. J. Immumol. 175 (2005) 3165-3176
33. Vicari A.P., Caux C., and Trinchieri G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin. Cancer Biol. 12 (2002) 33-42